CA3081163A1 - External preparation for treating trichophytosis unguium - Google Patents

External preparation for treating trichophytosis unguium Download PDF

Info

Publication number
CA3081163A1
CA3081163A1 CA3081163A CA3081163A CA3081163A1 CA 3081163 A1 CA3081163 A1 CA 3081163A1 CA 3081163 A CA3081163 A CA 3081163A CA 3081163 A CA3081163 A CA 3081163A CA 3081163 A1 CA3081163 A1 CA 3081163A1
Authority
CA
Canada
Prior art keywords
preparation
active substance
topical
topical preparation
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3081163A
Other languages
English (en)
French (fr)
Inventor
Nobuyuki Natori
Hiroyuki TAKABE
Takashi Ishimaru
Hiroshi Iseki
Keiichi KARASAWA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kaken Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd filed Critical Kaken Pharmaceutical Co Ltd
Publication of CA3081163A1 publication Critical patent/CA3081163A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
CA3081163A 2017-10-30 2018-10-29 External preparation for treating trichophytosis unguium Pending CA3081163A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-209136 2017-10-30
JP2017209136 2017-10-30
PCT/JP2018/040047 WO2019088005A1 (ja) 2017-10-30 2018-10-29 爪白癬治療用の外用製剤

Publications (1)

Publication Number Publication Date
CA3081163A1 true CA3081163A1 (en) 2019-05-09

Family

ID=66333195

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3081163A Pending CA3081163A1 (en) 2017-10-30 2018-10-29 External preparation for treating trichophytosis unguium

Country Status (14)

Country Link
US (1) US20210213002A1 (enExample)
EP (1) EP3705136A4 (enExample)
JP (2) JP6582158B1 (enExample)
KR (1) KR20200081432A (enExample)
CN (1) CN111295202B (enExample)
AU (1) AU2018358372A1 (enExample)
BR (1) BR112020008282A2 (enExample)
CA (1) CA3081163A1 (enExample)
IL (1) IL274100B2 (enExample)
MX (1) MX2020004491A (enExample)
RU (1) RU2020117569A (enExample)
SG (1) SG11202003820VA (enExample)
TW (1) TWI789448B (enExample)
WO (1) WO2019088005A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220119363A (ko) 2019-12-24 2022-08-29 가껭세이야꾸가부시기가이샤 에피나코나졸을 함유하는 의약
EP3981402A4 (en) * 2020-08-14 2022-08-10 BL&H Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF RINGWORM
KR102217617B1 (ko) * 2020-08-14 2021-02-19 비엘엔에이치 주식회사 백선의 예방 또는 치료용 약학적 조성물
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN122297526A (zh) 2022-05-16 2026-06-30 玛路弘株式会社 白癣治疗用组合物
WO2025028651A1 (ja) * 2023-08-02 2025-02-06 石原産業株式会社 爪白癬用外用剤
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
AU2024393766A1 (en) 2023-12-08 2026-06-18 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514385A (en) * 1981-10-05 1985-04-30 Alcon Laboratories, Inc. Anti-acne compositions
JPS58162514A (ja) * 1982-03-19 1983-09-27 Sumitomo Chem Co Ltd 外用ゲル製剤
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
NZ274711A (en) * 1993-09-29 1996-11-26 Alza Corp Composition for administration of active agent by application to a body surface or membrane comprising permeability enhancing amount of monoglyceride(s) and lactate ester(s)
AU5404399A (en) * 1998-09-10 2000-04-03 Ipr-Institute For Pharmaceutical Research Ag Topical application products
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US8048919B2 (en) * 2004-06-28 2011-11-01 Archer Daniels Midland Company Use of ethyl lactate as an excipient for pharmaceutical compositions
JP5061519B2 (ja) 2006-07-12 2012-10-31 大正製薬株式会社 抗真菌剤含有ｏ／ｗエマルション組成物
KR101184834B1 (ko) * 2007-08-27 2012-09-20 니혼노야쿠가부시키가이샤 진균성 피부염용제
NL2003711C2 (en) * 2009-10-27 2011-04-28 Shield Mark B V Aqueous composition for topical application, method of preparation, uses and device.
NL2003786C2 (en) * 2009-11-11 2010-07-30 Medner B V COMPOSITION FOR TOPICAL APPLICATION, USES THEREOF, APPLICATOR DEVICE AND KIT OF PARTS.
WO2012102404A1 (ja) 2011-01-30 2012-08-02 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 外用抗真菌剤
PH12014501000A1 (en) * 2011-11-04 2014-06-09 Agile Therapeutics Inc Dermal delivery compositions and methods
EP2895164A1 (en) * 2012-09-14 2015-07-22 Pola Pharma Inc. Pharmaceutical composition containing luliconazole
CA2934448A1 (en) * 2012-12-20 2014-06-26 Rajiv Bhushan Antimicrobial compositions
WO2014104149A1 (ja) * 2012-12-28 2014-07-03 大正製薬株式会社 皮膚適用製剤
CN103142458B (zh) * 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
KR102612453B1 (ko) * 2013-11-22 2023-12-08 다우 파마슈티컬 사이언시즈, 인코포레이티드 항­감염 방법，조성물，및 장치
JP5623671B1 (ja) * 2014-07-23 2014-11-12 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
WO2017047602A1 (ja) * 2015-09-18 2017-03-23 科研製薬株式会社 ビアリール誘導体及びそれを含有する医薬
JP2017209136A (ja) 2016-05-23 2017-11-30 澁谷工業株式会社 電子線殺菌装置

Also Published As

Publication number Publication date
TWI789448B (zh) 2023-01-11
MX2020004491A (es) 2020-08-13
RU2020117569A (ru) 2021-12-01
JPWO2019088005A1 (ja) 2019-11-14
IL274100A (en) 2020-06-30
WO2019088005A1 (ja) 2019-05-09
SG11202003820VA (en) 2020-05-28
RU2020117569A3 (enExample) 2021-12-01
EP3705136A1 (en) 2020-09-09
IL274100B2 (en) 2023-06-01
AU2018358372A1 (en) 2020-05-28
CN111295202B (zh) 2022-07-08
TW201922247A (zh) 2019-06-16
JP2020011967A (ja) 2020-01-23
JP6582158B1 (ja) 2019-09-25
EP3705136A4 (en) 2021-08-18
KR20200081432A (ko) 2020-07-07
BR112020008282A2 (pt) 2020-10-20
CN111295202A (zh) 2020-06-16
US20210213002A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
AU2018358372A1 (en) External preparation for treating trichophytosis unguium
AU2019213835B2 (en) Topical formulations comprising tofacitinib
US10391108B2 (en) Pharmaceutical tetracycline composition for dermatological use
KR101373955B1 (ko) 외용의 의약 조성물
US20100173965A1 (en) Antifungal composition
US20110092438A1 (en) Composition for external application comprising transcription factor decoy as active ingredient
JP2011500779A (ja) 新規製剤
US20090182004A1 (en) Imiquimod formulation
JP2012526727A (ja) 皮膚および爪の真菌感染症の局所治療に適した組成物
EP2403476A1 (en) Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail
CN103476396B (zh) 包含环状缩酚肽的混悬类型的局部制剂
US12551485B2 (en) Topical formulations of ruxolitinib with an organic amine pH adjusting agent for treatment of skin diseases
US20130210910A1 (en) Compositions suitable for the topical treatment of fungal infections of the skin and nails
US20100210681A1 (en) Aqueous pharmaceutical composition
HK40024555A (en) External preparation for treating trichophytosis unguium
HK40024555B (en) External preparation for treating trichophytosis unguium
CA3174475A1 (en) Topical pharmaceutical formulations of a cyclic depsipeptide
WO2014017411A1 (ja) 爪白癬治療用外用剤
KR20260046477A (ko) 조백선용 외용제
RU2660353C2 (ru) Способ и улучшенная фармацевтическая композиция для ускорения трансдермальной доставки ингибитора pde-5
US20120309753A1 (en) Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail
WO2019002362A1 (en) TOPICAL COMPOSITIONS OF CYCLOSPORIN A